NPM1 and acute myeloid leukemia: Seventeen patients at a median of age 56 years (range, 19–82 years) were treated, 15 (88%) had R/R AML, and 2 (12%) had R/R B-ALL; 9 (53%) had a KMT2A-r but none had an NPM1 mutation.